JP2023512294A - 天然ｄｎａまたは合成ｄｎａによって作製されたポックスウイルスベースのベクターおよびその使用法 - Google Patents

天然ｄｎａまたは合成ｄｎａによって作製されたポックスウイルスベースのベクターおよびその使用法 Download PDF

Info

Publication number
JP2023512294A
JP2023512294A JP2022547055A JP2022547055A JP2023512294A JP 2023512294 A JP2023512294 A JP 2023512294A JP 2022547055 A JP2022547055 A JP 2022547055A JP 2022547055 A JP2022547055 A JP 2022547055A JP 2023512294 A JP2023512294 A JP 2023512294A
Authority
JP
Japan
Prior art keywords
dna
fragments
sequence
sequences
poxvirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022547055A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512294A5 (enExample
Inventor
ドン ジェイ． ダイヤモンド
フェリックス ウッソウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of JP2023512294A publication Critical patent/JP2023512294A/ja
Publication of JP2023512294A5 publication Critical patent/JP2023512294A5/ja
Priority to JP2026033811A priority Critical patent/JP2026094336A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C12N2710/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/50—Vectors for producing vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2022547055A 2020-02-03 2021-02-02 天然ｄｎａまたは合成ｄｎａによって作製されたポックスウイルスベースのベクターおよびその使用法 Pending JP2023512294A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026033811A JP2026094336A (ja) 2020-02-03 2026-03-04 天然ｄｎａまたは合成ｄｎａによって作製されたポックスウイルスベースのベクターおよびその使用法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062969628P 2020-02-03 2020-02-03
US62/969,628 2020-02-03
US202063113803P 2020-11-13 2020-11-13
US63/113,803 2020-11-13
PCT/US2021/016247 WO2021158565A2 (en) 2020-02-03 2021-02-02 Poxvirus-based vectors produced by natural or synthetic dna and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026033811A Division JP2026094336A (ja) 2020-02-03 2026-03-04 天然ｄｎａまたは合成ｄｎａによって作製されたポックスウイルスベースのベクターおよびその使用法

Publications (2)

Publication Number Publication Date
JP2023512294A true JP2023512294A (ja) 2023-03-24
JP2023512294A5 JP2023512294A5 (enExample) 2024-02-09

Family

ID=77200801

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022547055A Pending JP2023512294A (ja) 2020-02-03 2021-02-02 天然ｄｎａまたは合成ｄｎａによって作製されたポックスウイルスベースのベクターおよびその使用法
JP2026033811A Pending JP2026094336A (ja) 2020-02-03 2026-03-04 天然ｄｎａまたは合成ｄｎａによって作製されたポックスウイルスベースのベクターおよびその使用法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026033811A Pending JP2026094336A (ja) 2020-02-03 2026-03-04 天然ｄｎａまたは合成ｄｎａによって作製されたポックスウイルスベースのベクターおよびその使用法

Country Status (10)

Country Link
EP (1) EP4100514A4 (enExample)
JP (2) JP2023512294A (enExample)
KR (1) KR20220148823A (enExample)
CN (1) CN115397998A (enExample)
AU (2) AU2021217073A1 (enExample)
BR (1) BR112022014738A2 (enExample)
CA (1) CA3168836A1 (enExample)
IL (1) IL294926A (enExample)
MX (1) MX2022009200A (enExample)
WO (1) WO2021158565A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3167052A1 (en) 2020-02-14 2021-08-19 Mary Jo Hauser Vaccines and uses thereof to induce an immune response to sars-cov2
EP4153228A4 (en) 2020-05-17 2024-07-10 City of Hope CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS
BR112023015467A2 (pt) 2021-02-02 2023-10-10 Geovax Inc Vetor viral de vaccinia ankara recombinante modificado, métodos para aumentar uma resposta imunológica a um antígeno alvo em um paciente e para prevenir, tratar ou induzir uma resposta imunológica contra um antígeno alvo, e, composição farmacêutica
CN115433741A (zh) * 2022-06-23 2022-12-06 广西大学 盖他病毒为载体表达报告蛋白的重组病毒的构建方法
CN118240879A (zh) * 2023-11-01 2024-06-25 上海市重大传染病和生物安全研究院 骨架质粒、重组质粒以及猴痘病毒颗粒和应用
CN119506355B (zh) * 2025-01-15 2025-10-17 中国人民解放军军事科学院军事医学研究院 一种用于重组痘病毒包装的载体系统及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019213452A1 (en) * 2018-05-02 2019-11-07 David Evans Synthetic chimeric vaccinia virus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019213452A1 (en) * 2018-05-02 2019-11-07 David Evans Synthetic chimeric vaccinia virus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NATURE METHODS, vol. 2, no. 2, JPN6025003669, 2005, pages 95 - 97, ISSN: 0005874233 *
PLOS ONE, vol. Vol.3, Issue 2, JPN6025003667, 2008, pages 1638 - 1, ISSN: 0005874232 *

Also Published As

Publication number Publication date
IL294926A (en) 2022-09-01
WO2021158565A3 (en) 2021-09-16
EP4100514A2 (en) 2022-12-14
WO2021158565A2 (en) 2021-08-12
EP4100514A4 (en) 2024-06-12
JP2026094336A (ja) 2026-06-09
CA3168836A1 (en) 2021-08-12
MX2022009200A (es) 2023-01-04
BR112022014738A2 (pt) 2022-10-11
AU2021217073A1 (en) 2022-08-18
CN115397998A (zh) 2022-11-25
AU2025287330A1 (en) 2026-01-22
KR20220148823A (ko) 2022-11-07

Similar Documents

Publication Publication Date Title
JP7118062B2 (ja) リサウイルス抗原を有するチンパンジーアデノウイルス構築物
AU2025287330A1 (en) Poxvirus-based vectors produced by natural or synthetic DNA and uses thereof
US5698202A (en) Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
US12584146B2 (en) Synthetic modified vaccinia Ankara (SMVA) based coronavirus vaccines
CN104838000B (zh) 一种递送ul128复合体和预防cmv感染的mva疫苗
US11844833B2 (en) Expression system for expressing herpesvirus glycoprotein complexes
JP2019505205A (ja) Ｈｂｖを処置するための手段及び方法
ES2424847T3 (es) Genes del virus de la fiebre aftosa que expresan avipox recombinantes
Im et al. MVA as a vector for vaccines against HIV-1
US20250215456A1 (en) Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
US20090053256A1 (en) Poxvirus Methods And Compositions
JP2023528984A (ja) コロナウイルス病に対する組換え修飾ワクシニアウイルスアンカラ（ｍｖａ）ワクチン
Thornburg et al. Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge
US20250161435A1 (en) Multivalent kaposi sarcoma-associated herpesvirus-like particles and uses thereof
US20110064769A1 (en) Vv promoter-driven overexpression of recombinant antigens
US7972605B2 (en) Modified vaccinia ankara virus vaccine
WO2026104601A1 (en) Viral vectors for enhanced immune responses to multimeric protein particle displayed antigens
JP2025524459A (ja) エプスタイン・バー・ウイルスワクチン
Smith Vaccinia Virus as a Carrier of Vaccine Antigens
EA052954B1 (ru) Вакцина против вируса эпштейна-барр

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221028

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260603

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260618

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260717